专利检索 ap:("The Board of Trustees of the Leland Stanford Junior University") AND inv:"Tom J. Wandless" 第 1 页

1.

发明授权
Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling 有权

公开(公告)号：US11938153B2

公开(公告)日：2024-03-26

申请号：US16499760

申请日：2018-03-30

申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

发明人： Rachel Lynn , Crystal Mackall , Tom J. Wandless , Evan Weber

IPC分类号： A61K35/17 , A61K31/5025 , A61K31/506 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N9/90

CPC分类号： A61K35/17 , A61K31/5025 , A61K31/506 , A61P35/00 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/3084 , C12N5/0636 , C12N9/90 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N2501/727 , C12N2510/00

摘要： The present invention relates to T cell compositions and methods of using the same in the context of therapy and treatment. In particular, the invention provides chimeric antigen receptor (CAR) T cells that are modified to maintain functionality under conditions in which unmodified CAR T cells display exhaustion. Compositions and methods disclosed herein find use in inhibiting or reversing CAR T cell exhaustion (e.g., by modulating CAR surface expression) thereby enhancing CAR T cell function. Compositions and methods of the invention fmd use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

2.

发明公开
Methods of Treating T Cell Exhaustion by Inhibiting or Modulating T Cell Receptor Signaling 审中-公开

公开(公告)号：US20240293461A1

公开(公告)日：2024-09-05

申请号：US18583096

申请日：2024-02-21

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Rachel Lynn , Crystal Mackall , Tom J. Wandless , Evan Weber

IPC分类号： A61K35/17 , A61K31/5025 , A61K31/506 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N9/90

CPC分类号： A61K35/17 , A61K31/5025 , A61K31/506 , A61P35/00 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/3084 , C12N5/0636 , C12N9/90 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N2501/727 , C12N2510/00

摘要： The present invention relates to T cell compositions and methods of using the same in the context of therapy and treatment. In particular, the invention provides chimeric antigen receptor (CAR) T cells that are modified to maintain functionality under conditions in which unmodified CAR T cells display exhaustion. Compositions and methods disclosed herein find use in inhibiting or reversing CAR T cell exhaustion (e.g., by modulating CAR surface expression) thereby enhancing CAR T cell function. Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.